Guus M. Vermeulen

Guus M. Vermeulen

Auto-generated profile, based on publicly available information

Guus M. Vermeulen

Hand and Wrist Center, Xpert Clinics, Flight Forum 130, 5657 DD, Eindhoven, the Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2023 in Journal of Bone and Joint Surgery
Verified
Journal Article
Open access
LLLisa M.J. Esteban Lopez
Lisa M.J. Esteban Lopez
LHLisa Hoogendam
Lisa Hoogendam
GVGuus M. Vermeulen
Guus M. Vermeulen
JTJonathan Tsehaie
Jonathan Tsehaie
HSHarm P. Slijper
Harm P. Slijper
TGThe Hand-Wrist Study Group
The Hand-Wrist Study Group
Background: Although nonsurgical treatment of thumb carpometacarpal (CMC-1) osteoarthritis (OA) provides short-term improvement, the durability of these effects beyond 1 year is unknown. In this study, we investigated patient-reported pain and limitations in activities of daily living (ADL) at >5 years following nonsurgical treatment (i.e., exercise therapy and use of an orthosis) for CMC-1 OA. We hypothesized that pain and limitations in ADL would not worsen after 12 months. Secondary outcomes were satisfaction with treatment results and health-related quality of life at >5 years of follow-up and the rate of conversion to surgery. Methods: This was a multicenter, prospective cohort study using 2 overlapping samples. The change in the Michigan Hand Outcomes Questionnaire (MHQ) subscales of pain and ADL between 12 months and >5 years was the primary outcome as measured in the first sample (n = 170), which consisted of patients who did not undergo conversion to surgery. Additional measurement time points included baseline and 3 months. We evaluated conversion to surgery in a second sample, which included all patients who responded to the invitation for this follow-up study (n = 217). Results: At a median follow-up of 6.6 years (range, 5.1 to 8.7 years), the score on the MHQ pain subscale did not differ significantly from that at 12 months. The score on the MHQ ADL improved by 4.4 points (95% confidence interval [CI],1.5 to 7.2) compared with 12 months, but this was not clinically relevant. At >5 years, 5% of the patients rated their satisfaction as “poor,” 14% as “moderate,” 26% as “fair,” 39% as “good,” and 16% as “excellent.” The median EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) index score was 0.852 (range, 0.135 to 1). The rate of conversion to surgery was 22% (95% CI,16.4% to 27.7%) at a median follow-up of 7 years (range, 5.5 to 9.0 years). Conclusions: We found positive outcomes at >5 years of follow-up for nonsurgical treatment of CMC-1 OA, with no worsening of pain or of limitations in ADL after 12 months. Our findings support nonsurgical treatment as the first treatment choice and suggest that treatment effects are sustainable. Level of evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

24 October 2025 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
RWRobbert M. Wouters
Robbert M. Wouters
LLLisa Mj Esteban Lopez
Lisa Mj Esteban Lopez
SHStella Cm Heemskerk
Stella Cm Heemskerk
SBSita Ma Bierma-Zeinstra
Sita Ma Bierma-Zeinstra
GKGerald A. Kraan
Gerald A. Kraan
RSRuud Selles
Ruud Selles
To compare the effectiveness and costs of an orthosis + exercise therapy with only an orthosis on pain at 3 months and conversion to surgery <1 year in patients with thumb carpometacarpal (CMC-1) osteoarthritis (OA). Multicenter, single-blinded, randomized controlled trial. Eighteen outpatient hand surgery and therapy clinics in the Netherlands. Adult patients with CMC-1 OA. Orthosis + exercise therapy versus orthosis-only. Pain at 3 months (Michigan Hand Outcomes Questionnaire pain subscale) and conversion to surgery <1 year. We included 166 patients (81 orthosis + exercise, 85 orthosis-only). There was no difference between the orthosis + exercise group and the orthosis-only group in pain at three months (least mean square difference 3.7 [95% CI -1.0 to 8.3]). Conversion to surgery was 4.9% (n=4) in the orthosis + exercise group and 9.4% (n=8) in the orthosis-only group, which was not significantly different (risk difference 4.7% [-3.3% to 12.2%) due to the low conversion to surgery rates. The total societal costs for orthosis + exercise were 37% (-€825 [-2072 to 421]) lower per patient than orthosis-only. The orthosis + exercise group had favorable outcomes in MHQ subscale activities of daily living scores (6mo), work ability (all time points), satisfaction with hand (3mo), the MHQ total score (3mo, 6mo), satisfaction with treatment results (all except 6mo), grip strength (6w), and illness perceptions (3mo). In patients with CMC-1 OA, an orthosis + exercise therapy is preferred over orthosis-only because of the favorable secondary outcomes. ClinicalTrials.gov: NCT05772715.